Frontier Biotechnologies(SH:688221) KAIYUAN SECURITIES·2026-03-01 10:45Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the ongoing collaboration between GSK and Chinese company Frontier Bio in the siRNA field, indicating that Chinese enterprises are gaining international recognition for their R&D capabilities [6][7] - The pharmaceutical sector saw a 0.5% increase, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th among 31 sub-industries [8][22] - The report recommends focusing on innovative drugs and their supply chains, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [9] Summary by Sections GSK Collaboration and Market Trends - GSK has been actively engaging in partnerships related to small nucleic acids, with significant pipelines in ASO and siRNA. Notably, GSK's collaboration with Frontier Bio involves a total transaction value of up to $1.003 billion for two pipelines [6][7][18] - The report notes that GSK's recent partnerships reflect the growing technical strength and platform value of Chinese companies in the small nucleic acid drug development sector [7][17] Market Performance - In the week of February 4, 2026, the pharmaceutical sector increased by 0.5%, with the medical consumables sector showing the highest growth at 3.99%. Conversely, the medical R&D outsourcing sector experienced the largest decline at -2.2% [8][22][23] - Monthly data indicates that since the beginning of 2026, the overall market has been on an upward trend, with various sectors performing differently [22] Recommendations - The report continues to favor innovative drugs and their associated industries, recommending specific companies such as Heng Rui Medicine, WuXi AppTec, and others for investment [9][26] - Weekly recommendations include companies like Bai Li Tian Heng and Kanglong Huacheng, indicating a strategic focus on firms with strong growth potential in the pharmaceutical sector [9]